Intravenous Tissue Plasminogen Activator Treatment for Acute Ischemic Stroke in the REGARDS Study (P7.138)

CONCLUSIONS:Our study of unselected US hospitals showed low tPA utilization. Documented reasons for non-use were suboptimal with the lowest among patients not evaluated by a stroke team. Our sample was not limited to hospitals participating in national quality improvement programs, thus increasing generalizability. Strategies that focus on earlier hospital arrival and educating both the public and healthcare field to increase tPA utilization are urgently needed.Disclosure: Dr. Sands has nothing to disclose. Dr. Albright has nothing to disclose. Dr. Blackburn has nothing to disclose. Dr. Boehme has nothing to disclose. Dr. Howard has received personal compensation for activities with Bayer Healthcare and Abbott. Dr. Howard has received research support from Amgen and Bayer Healthcare. Dr. Howard has nothing to disclose. Dr. Judd has nothing to disclose. Dr. Kissela has received personal compensation for activities with Allergan, Inc., AbbVie, and Reata Pharmaceuticals. Dr. Limdi has nothing to disclose. Dr. Rhodes has nothing to disclose. Dr. Shiue has nothing to disclose. Dr. Sisson has nothing to disclose. Dr. Safford has received research support from Amgen Inc. and Pfizer Inc.

Source: Neurology - April 8, 2015 Category: Neurology Authors: Sands, K., Albright, K., Blackburn, J., Boehme, A., Howard, G., Howard, V., Judd, S., Kissela, B., Limdi, N., Rhodes, D., Shiue, H., Sisson, A., Safford, M. Tags: Cerebrovascular Disease and Interventional Neurology: Race, Ethnicity, and Stroke Source Type: research